Goldman Sachs Upgrades Fulcrum Therapeutics to Buy, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins upgraded Fulcrum Therapeutics (FULC) from Neutral to Buy and increased the price target from $6 to $15.

May 14, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs upgraded Fulcrum Therapeutics to Buy and raised the price target to $15, indicating a positive outlook on the stock.
Upgrades by major financial institutions like Goldman Sachs typically lead to increased investor confidence and can drive up the stock price in the short term. The substantial raise in price target from $6 to $15 reflects a strong positive reassessment of the company's value and growth prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100